These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

413 related articles for article (PubMed ID: 25742472)

  • 21. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104--a randomized trial of the German AIO CRC study group.
    Moosmann N; von Weikersthal LF; Vehling-Kaiser U; Stauch M; Hass HG; Dietzfelbinger H; Oruzio D; Klein S; Zellmann K; Decker T; Schulze M; Abenhardt W; Puchtler G; Kappauf H; Mittermüller J; Haberl C; Schalhorn A; Jung A; Stintzing S; Heinemann V
    J Clin Oncol; 2011 Mar; 29(8):1050-8. PubMed ID: 21300933
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Efficacy and safety of bevacizumab-based combination regimens in patients with previously untreated metastatic colorectal cancer: final results from a randomised phase II study of bevacizumab plus 5-fluorouracil, leucovorin plus irinotecan versus bevacizumab plus capecitabine plus irinotecan (FNCLCC ACCORD 13/0503 study).
    Ducreux M; Adenis A; Pignon JP; François E; Chauffert B; Ichanté JL; Boucher E; Ychou M; Pierga JY; Montoto-Grillot C; Conroy T
    Eur J Cancer; 2013 Apr; 49(6):1236-45. PubMed ID: 23352604
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined assessment of epidermal [corrected] growth factor receptor dual color in situ hybridization and immunohistochemistry with downstream gene mutations in prediction of response to the anti-EGFR therapy for patients with metastatic colorectal cancer.
    Takahashi N; Yamada Y; Taniguchi H; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y
    Arch Med Res; 2014 Jul; 45(5):366-74. PubMed ID: 24830936
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The efficacy and safety of panitumumab administered concomitantly with FOLFIRI or Irinotecan in second-line therapy for metastatic colorectal cancer: the secondary analysis from STEPP (Skin Toxicity Evaluation Protocol With Panitumumab) by KRAS status.
    Mitchell EP; Piperdi B; Lacouture ME; Shearer H; Iannotti N; Pillai MV; Xu F; Yassine M
    Clin Colorectal Cancer; 2011 Dec; 10(4):333-9. PubMed ID: 22000810
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study.
    Antonuzzo L; Giommoni E; Pastorelli D; Latiano T; Pavese I; Azzarello D; Aieta M; Pastina I; Di Fabio F; Bertolini A; Corsi DC; Mogavero S; Angelini V; Pazzagli M; Di Costanzo F
    World J Gastroenterol; 2015 Jun; 21(23):7281-8. PubMed ID: 26109816
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An open-label, single-arm, phase 2 trial of panitumumab plus FOLFIRI as second-line therapy in patients with metastatic colorectal cancer.
    Cohn AL; Shumaker GC; Khandelwal P; Smith DA; Neubauer MA; Mehta N; Richards D; Watkins DL; Zhang K; Yassine MR
    Clin Colorectal Cancer; 2011 Sep; 10(3):171-7. PubMed ID: 21855038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PIK3CA, BRAF, and PTEN status and benefit from cetuximab in the treatment of advanced colorectal cancer--results from NCIC CTG/AGITG CO.17.
    Karapetis CS; Jonker D; Daneshmand M; Hanson JE; O'Callaghan CJ; Marginean C; Zalcberg JR; Simes J; Moore MJ; Tebbutt NC; Price TJ; Shapiro JD; Pavlakis N; Gibbs P; Van Hazel GA; Lee U; Haq R; Virk S; Tu D; Lorimer IA;
    Clin Cancer Res; 2014 Feb; 20(3):744-53. PubMed ID: 24218517
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
    Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
    Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: results from the Australasian phase III MAX study.
    Carter HE; Zannino D; John Simes R; Schofield DJ; Howard K; Zalcberg JR; Price TJ; Tebbutt NC
    Eur J Cancer; 2014 Feb; 50(3):535-43. PubMed ID: 24215848
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prevalent KRAS exon 2 c.35 G>A mutation in metastatic colorectal cancer patients: A biomarker of worse prognosis and potential benefit of bevacizumab-containing intensive regimens?
    Bruera G; Cannita K; Tessitore A; Russo A; Alesse E; Ficorella C; Ricevuto E
    Crit Rev Oncol Hematol; 2015 Mar; 93(3):190-202. PubMed ID: 25459669
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
    Constantinidou A; Cunningham D; Shurmahi F; Asghar U; Barbachano Y; Khan A; Mudan S; Rao S; Chau I
    Clin Colorectal Cancer; 2013 Mar; 12(1):15-22. PubMed ID: 23021126
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Proangiogenic tumor proteins as potential predictive or prognostic biomarkers for bevacizumab therapy in metastatic colorectal cancer.
    Bruhn MA; Townsend AR; Khoon Lee C; Shivasami A; Price TJ; Wrin J; Arentz G; Tebbutt NC; Hocking C; Cunningham D; Hardingham JE;
    Int J Cancer; 2014 Aug; 135(3):731-41. PubMed ID: 24374727
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group.
    Simkens LH; van Tinteren H; May A; ten Tije AJ; Creemers GJ; Loosveld OJ; de Jongh FE; Erdkamp FL; Erjavec Z; van der Torren AM; Tol J; Braun HJ; Nieboer P; van der Hoeven JJ; Haasjes JG; Jansen RL; Wals J; Cats A; Derleyn VA; Honkoop AH; Mol L; Punt CJ; Koopman M
    Lancet; 2015 May; 385(9980):1843-52. PubMed ID: 25862517
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [KRAS mutation does not influence oxaliplatin or irinotecan efficacy, in association with bevacizumab, in first line treatment of metastatic colorectal cancer].
    Cabart M; Frénel JS; Campion L; Ramée JF; Dupuis O; Senellart H; Hiret S; Douillard JY; Bennouna J
    Bull Cancer; 2016 Jun; 103(6):541-51. PubMed ID: 27155924
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy of triplet combination chemotherapy with oxaliplatin, irinotecan and capecitabine (OCX) in metastatic colorectal cancer in relation to RAS/RAF mutation status: results of a retrospective analysis.
    Brunner S; von Moos R; Mey U; Camenisch Gross U; Freyholdt T; Cathomas R
    Oncol Res Treat; 2014; 37(11):646-52. PubMed ID: 25427581
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer.
    Peeters M; Price TJ; Cervantes A; Sobrero AF; Ducreux M; Hotko Y; André T; Chan E; Lordick F; Punt CJ; Strickland AH; Wilson G; Ciuleanu TE; Roman L; Van Cutsem E; Tzekova V; Collins S; Oliner KS; Rong A; Gansert J
    J Clin Oncol; 2010 Nov; 28(31):4706-13. PubMed ID: 20921462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Paclitaxel and bevacizumab with or without capecitabine as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a multicentre, open-label, randomised phase 2 trial.
    Lam SW; de Groot SM; Honkoop AH; Jager A; ten Tije AJ; Bos MM; Linn SC; van den Bosch J; Kroep JR; Braun JJ; van Tinteren H; Boven E;
    Eur J Cancer; 2014 Dec; 50(18):3077-88. PubMed ID: 25459393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic value of cetuximab-related skin toxicity in metastatic colorectal cancer patients and its correlation with parameters of the epidermal growth factor receptor signal transduction pathway: results from a randomized trial of the GERMAN AIO CRC Study Group.
    Stintzing S; Kapaun C; Laubender RP; Jung A; Neumann J; Modest DP; Giessen C; Moosmann N; Wollenberg A; Kirchner T; Heinemann V
    Int J Cancer; 2013 Jan; 132(1):236-45. PubMed ID: 22644776
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer: interim efficacy results of the randomised, open-label, non-inferiority, phase 3 TURANDOT trial.
    Lang I; Brodowicz T; Ryvo L; Kahan Z; Greil R; Beslija S; Stemmer SM; Kaufman B; Zvirbule Z; Steger GG; Melichar B; Pienkowski T; Sirbu D; Messinger D; Zielinski C;
    Lancet Oncol; 2013 Feb; 14(2):125-33. PubMed ID: 23312888
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gastrointestinal perforation in metastatic colorectal cancer patients with peritoneal metastases receiving bevacizumab.
    Roohullah A; Wong HL; Sjoquist KM; Gibbs P; Field K; Tran B; Shapiro J; Mckendrick J; Yip D; Nott L; Gebski V; Ng W; Chua W; Price T; Tebbutt N; Chantrill L
    World J Gastroenterol; 2015 May; 21(17):5352-8. PubMed ID: 25954110
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.